Feng-Ting Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Feng-Ting Liu has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Li Jia
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
20 shared publications Adrian C. Newland
Division of Haemato-Oncology and Immunophenotyping Section, Department of Haematology, Barts and The London National Health Service (NHS) Trust, London, United Kingdom
9 shared publicationsJohn G. Gribben
Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK
7 shared publicationsSamir G. Agrawal
Division of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust and Queen Mary University of London, London, United Kingdom
7 shared publications- Samir G. Agrawal
Blizard Institute of Cell and Molecular Science, Queen Mary University of London, London, United Kingdom Department of Haemato-Oncology, St. Bartholomew's Hospital, London, United Kingdom
3 shared publications Stephen M. Kelsey
Department of Haematology/Oncology, St. Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK
3 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (5) , 1-13
Curcumin induces and enhances the PARP1‑mediated parthanatos in diffuse large B cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults. Although the development and application of novel therapeutic agents have improved patient survival, primary drug resistance and the management of relapsed/refractory disease remain major challenges. Curcumin, a natural polyphenol, exhibits broad-spectrum antitumor activity. However, its anti-DLBCL efficacy and underlying mechanisms have not been well characterized. The present study investigated whether curcumin inhibited DLBCL by inducing parthanatos, a form of programmed cell death. Results showed that curcumin exerted a concentration-dependent, caspase-independent cytotoxic effect on DLBCL cells, accompanied by an increase in DAPI-positive/propidium iodide-positive cells. Western blotting analysis revealed that curcumin upregulated poly(ADP-ribose) and poly(ADP-ribose) polymerase 1 (PARP-1) expression in whole-cell lysates. Moreover, nuclear expression levels of apoptosis-inducing factor (AIF) and macrophage migration inhibitory factor were significantly elevated compared with their cytoplasmic levels. Immunofluorescence staining further confirmed the increased nuclear localization of PARP-1 and AIF. Furthermore, low-dose curcumin combined with ultraviolet B (UVB) irradiation synergistically induced parthanatos in DLBCL cells. Notably, olaparib, a specific PARP-1 inhibitor, attenuated activation of parthanatos induced by curcumin alone or in combination with UVB. In summary, the present findings suggest that curcumin inhibits DLBCL cell proliferation through PARP1-mediated parthanatos and exhibits synergistic effects with UVB irradiation.
- 30 March 2026
- Published by Spandidos Publications in Oncology Letters
- Vol. 31 (5) , 1-13
Open AccessCurcumin induces and enhances the PARP1‑mediated parthanatos in diffuse large B cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma in adults. Although the development and application of novel therapeutic agents have improved patient survival, primary drug resistance and the management of relapsed/refractory disease remain major challenges. Curcumin, a natural polyphenol, exhibits broad-spectrum antitumor activity. However, its anti-DLBCL efficacy and underlying mechanisms have not been well characterized. The present study investigated whether curcumin inhibited DLBCL by inducing parthanatos, a form of programmed cell death. Results showed that curcumin exerted a concentration-dependent, caspase-independent cytotoxic effect on DLBCL cells, accompanied by an increase in DAPI-positive/propidium iodide-positive cells. Western blotting analysis revealed that curcumin upregulated poly(ADP-ribose) and poly(ADP-ribose) polymerase 1 (PARP-1) expression in whole-cell lysates. Moreover, nuclear expression levels of apoptosis-inducing factor (AIF) and macrophage migration inhibitory factor were significantly elevated compared with their cytoplasmic levels. Immunofluorescence staining further confirmed the increased nuclear localization of PARP-1 and AIF. Furthermore, low-dose curcumin combined with ultraviolet B (UVB) irradiation synergistically induced parthanatos in DLBCL cells. Notably, olaparib, a specific PARP-1 inhibitor, attenuated activation of parthanatos induced by curcumin alone or in combination with UVB. In summary, the present findings suggest that curcumin inhibits DLBCL cell proliferation through PARP1-mediated parthanatos and exhibits synergistic effects with UVB irradiation.
- Open Access
- 1 December 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (24) , 1769
Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study Xinrui Chen, Huaqing Wang, Xiuhua Sun, Liping Su, Fengting Liu, Ke Zhao, Liye Xu, Shaohua Wu, Teng Song
- 1 December 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (24) , 1769
Open AccessSafety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study
Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study Xinrui Chen, Huaqing Wang, Xiuhua Sun, Liping Su, Fengting Liu, Ke Zhao, Liye Xu, Shaohua Wu, Teng Song
- Open Access
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 4951692
Comprehensive Analysis of lncRNA‐Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms’ Tumor
Wilms’ tumor (WT) is the most common type of childhood kidney cancer, and most cases present with favorable histology and respond well to standard treatment. However, a subset of patients with WT is diagnosed with bilateral, relapsed, and high‐risk tumors which remain the leading cause of cancer‐related death in children. Long noncoding RNAs (lncRNAs) and their aberrant expression have currently been attracting great attention as oncogenes or tumor suppressors during tumor initiation and progression. So far, their roles and related competitive endogenous RNA (ceRNA) network remain unelucidated in nephroblastoma pathogenesis. We comprehensively integrated lncRNA, microRNA (miRNA), and messenger RNA (mRNA) expression profiles from the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database and screened out differentially expressed mRNAs (DEMs), lncRNAs (DELs), and miRNAs (DEMis) to construct a ceRNA network based on the information generated from miRcode, miRTarBase, TargetScan, and miRDB. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to analyze the functional characteristics of DEMs in the ceRNA network. The interaction between protein molecules was also analyzed by establishing a protein‐protein interaction network. Finally, prognosis‐related biomarkers were identified via survival analysis. Initially, 1647 DELs, 115 DEMis, and 3280 DEMs (|log FC| > 2; FDR < 0.01) were obtained using the R package. Next, we constructed a lncRNA‐miRNA‐mRNA network (ceRNA network), in which 176 DELs, 24 DEMis, and 141 DEMs were identified. Furthermore, 148 functional enrichment terms from GO were identified and 29 KEGG pathways were found to be significantly enriched. We also integrated patient clinical information to analyze the association between DERNAs and patient prognosis. We found that high expression of 8 DELs (LINC00473, AL445228.2, DENND5B−AS1, DLEU2, AC123595.1, AC135178.1, LINC00535, and LMO7−AS1) and 4 DEMs (CEP55, DEPDC1, PHF19, and TRIM36) correlated with poor survival in a patient with WT, whereas high expression of 2 DELs (MEG3 and RMST), 1 DEM (KIAA0922), and 1 DEMi (hsa−mir−200a) could possibly lead to better clinical outcomes. For the first time, the present study provided a novel insight into lncRNA‐related ceRNA networks and identified potential prognostic biomarkers in Wilms’ tumor.
- 1 January 2020
- Published by Wiley in BioMed Research International
- Vol. 2020 (1) , 4951692
Open AccessComprehensive Analysis of lncRNA‐Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms’ Tumor
Wilms’ tumor (WT) is the most common type of childhood kidney cancer, and most cases present with favorable histology and respond well to standard treatment. However, a subset of patients with WT is diagnosed with bilateral, relapsed, and high‐risk tumors which remain the leading cause of cancer‐related death in children. Long noncoding RNAs (lncRNAs) and their aberrant expression have currently been attracting great attention as oncogenes or tumor suppressors during tumor initiation and progression. So far, their roles and related competitive endogenous RNA (ceRNA) network remain unelucidated in nephroblastoma pathogenesis. We comprehensively integrated lncRNA, microRNA (miRNA), and messenger RNA (mRNA) expression profiles from the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) database and screened out differentially expressed mRNAs (DEMs), lncRNAs (DELs), and miRNAs (DEMis) to construct a ceRNA network based on the information generated from miRcode, miRTarBase, TargetScan, and miRDB. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to analyze the functional characteristics of DEMs in the ceRNA network. The interaction between protein molecules was also analyzed by establishing a protein‐protein interaction network. Finally, prognosis‐related biomarkers were identified via survival analysis. Initially, 1647 DELs, 115 DEMis, and 3280 DEMs (|log FC| > 2; FDR < 0.01) were obtained using the R package. Next, we constructed a lncRNA‐miRNA‐mRNA network (ceRNA network), in which 176 DELs, 24 DEMis, and 141 DEMs were identified. Furthermore, 148 functional enrichment terms from GO were identified and 29 KEGG pathways were found to be significantly enriched. We also integrated patient clinical information to analyze the association between DERNAs and patient prognosis. We found that high expression of 8 DELs (LINC00473, AL445228.2, DENND5B−AS1, DLEU2, AC123595.1, AC135178.1, LINC00535, and LMO7−AS1) and 4 DEMs (CEP55, DEPDC1, PHF19, and TRIM36) correlated with poor survival in a patient with WT, whereas high expression of 2 DELs (MEG3 and RMST), 1 DEM (KIAA0922), and 1 DEMi (hsa−mir−200a) could possibly lead to better clinical outcomes. For the first time, the present study provided a novel insight into lncRNA‐related ceRNA networks and identified potential prognostic biomarkers in Wilms’ tumor.
- Open Access
- 15 April 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (5) , 1-15
Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma
High mobility group box 1 (HMGB1) protein in the tumor microenvironment actively contributes to tumor progression but its role in diffuse large B-cell lymphoma (DLBCL) is unknown. The aim of this study was to determine the mechanism by which HMGB1 promotes tumor growth in DLBCL and whether blockade of HMGB1 signaling pathway could inhibit tumorigenesis. We report that HMGB1 promotes proliferation of DLBCL cells by activation of AKT, extracellular signal-regulated kinases 1/2 (ERK1/2), signal transducer and activator of transcription 3 (STAT3) and SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (Src). Ethyl pyruvate (EP), an anti-inflammatory agent, inhibits HMGB1 active release from DLBCL cells and significantly inhibited proliferation of DLBCL cells in vitro. Treatment with EP significantly prevented and inhibited tumor growth in vivo and prolonged DLBCL-bearing mice survival. EP significantly downregulated HMGB1 expression and phosphorylation of Src and ERK1/2 in mice lymphoma tissue. EP induced accumulation of the cell cycle inhibitor p27 but downregulated expression of cyclin-dependent kinase 2 (CDK2). Increased nuclear translocation of p27 interacted with CDK2 and cyclin A, which led to blockade of cell cycle progression at the G1 to S phase transition. In conclusion, we demonstrated for the first time that blockade of HMGB1-mediated signaling pathway by EP effectively inhibited DLBCL tumorigenesis and disease progression.
- 15 April 2019
- Published by Springer Nature in Cell Death & Disease
- Vol. 10 (5) , 1-15
Open AccessBlockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma
High mobility group box 1 (HMGB1) protein in the tumor microenvironment actively contributes to tumor progression but its role in diffuse large B-cell lymphoma (DLBCL) is unknown. The aim of this study was to determine the mechanism by which HMGB1 promotes tumor growth in DLBCL and whether blockade of HMGB1 signaling pathway could inhibit tumorigenesis. We report that HMGB1 promotes proliferation of DLBCL cells by activation of AKT, extracellular signal-regulated kinases 1/2 (ERK1/2), signal transducer and activator of transcription 3 (STAT3) and SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (Src). Ethyl pyruvate (EP), an anti-inflammatory agent, inhibits HMGB1 active release from DLBCL cells and significantly inhibited proliferation of DLBCL cells in vitro. Treatment with EP significantly prevented and inhibited tumor growth in vivo and prolonged DLBCL-bearing mice survival. EP significantly downregulated HMGB1 expression and phosphorylation of Src and ERK1/2 in mice lymphoma tissue. EP induced accumulation of the cell cycle inhibitor p27 but downregulated expression of cyclin-dependent kinase 2 (CDK2). Increased nuclear translocation of p27 interacted with CDK2 and cyclin A, which led to blockade of cell cycle progression at the G1 to S phase transition. In conclusion, we demonstrated for the first time that blockade of HMGB1-mediated signaling pathway by EP effectively inhibited DLBCL tumorigenesis and disease progression.
- Open Access
- 8 January 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (8) , 13994-14006
Increased autocrine interleukin‐6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) remains incurable with current standard therapy. We have previously reported that an increased expression of interleukin‐6 (IL‐6) receptor CD126 leads to resistance of CLL cells to chemotherapy and worse prognosis for patients with CLL. In this study, we determine whether autocrine IL‐6 production by CLL B cells is associated with poor clinical outcome and explore IL‐6‐mediated survival mechanism in primary CLL cells. Our results demonstrate that higher levels of autocrine IL‐6 are significantly associated with shorter absolute lymphocyte doubling time, patients received treatment, without complete remission, advanced Binet stages, 17p/11q deletion, and shorter time to first time treatment and progression‐free survival. IL‐6 activated both STAT3 and nuclear factor kappa B (NF‐κB) in primary CLL cells. Blocking IL‐6 receptor and JAK2 inhibited IL‐6‐mediated activation of STAT3 and NF‐κB. Our study demonstrates that an increased autocrine IL‐6 production by CLL B‐cells are associated with worse clinical outcome for patients with CLL. IL‐6 promotes CLL cell survival by activating both STAT3 and NF‐κB through diverse signaling cascades. Neutralizing IL‐6 or blocking IL‐6 receptor might contribute overcoming the resistance of CLL cells to chemotherapy. We propose that the measurement of autocrine IL‐6 could be a useful approach to predict clinical outcome.
- 8 January 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (8) , 13994-14006
Open AccessIncreased autocrine interleukin‐6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) remains incurable with current standard therapy. We have previously reported that an increased expression of interleukin‐6 (IL‐6) receptor CD126 leads to resistance of CLL cells to chemotherapy and worse prognosis for patients with CLL. In this study, we determine whether autocrine IL‐6 production by CLL B cells is associated with poor clinical outcome and explore IL‐6‐mediated survival mechanism in primary CLL cells. Our results demonstrate that higher levels of autocrine IL‐6 are significantly associated with shorter absolute lymphocyte doubling time, patients received treatment, without complete remission, advanced Binet stages, 17p/11q deletion, and shorter time to first time treatment and progression‐free survival. IL‐6 activated both STAT3 and nuclear factor kappa B (NF‐κB) in primary CLL cells. Blocking IL‐6 receptor and JAK2 inhibited IL‐6‐mediated activation of STAT3 and NF‐κB. Our study demonstrates that an increased autocrine IL‐6 production by CLL B‐cells are associated with worse clinical outcome for patients with CLL. IL‐6 promotes CLL cell survival by activating both STAT3 and NF‐κB through diverse signaling cascades. Neutralizing IL‐6 or blocking IL‐6 receptor might contribute overcoming the resistance of CLL cells to chemotherapy. We propose that the measurement of autocrine IL‐6 could be a useful approach to predict clinical outcome.
- Open Access
- 16 November 2018
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 141 (1) , 71-81
Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy
Background The prognosis in patients with gliomas after surgical resection followed by radiotherapy and/or chemotherapy is still very poor. The pro-apoptotic protein Bax, a short-lived protein in cancers, plays important roles in the sensitivity of glioma cells to spontaneous and therapy-induced apoptosis but and its prognostic value in gliomas is unknown. Methods By an immunohistochemical method, we determined Bax protein expression from 96 patients with gliomas after curative resection. Two statistical analyses were performed to evaluate the prognostic significance of Bax protein: an independent continuous and a multivariate categorical analysis, with test/validation set-defined cut points, and Kaplan–Meier estimated outcome measures of overall survival (OS) and relapse-free survival (RFS). Results Bax protein levels in glioblastoma were significantly decreased compared with grade II gliomas. Lower levels of Bax expression confer worse OS (continuous P = 0.025; categorical P = 0.003) and RFS (continuous P = 0.014; categorical P < 0.0001) and negatively correlate with the grades of gliomas. Patients underwent radiotherapy followed by surgical resection showed significantly increased OS (median = 45 vs. 17 months) and RFS (median = 39 vs. 16 months). Patients with higher levels of Bax and radiotherapy showed greatly increased survival rates (median OS = 66 months and median RFS = 105 months). Lower expression of Bax also confers inferior clinical outcome for gliomas patients after chemotherapy with temozolomide (OS and RFS P < 0.0001). Conclusion Decreased expression of Bax correlates with poor clinical outcome in patients with gliomas. We propose that Bax protein levels can be used as a reliable prognostic marker for risk-stratify patients with gliomas after curative resection and radiotherapy and/or chemotherapy.
- 16 November 2018
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 141 (1) , 71-81
Open AccessLower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy
Background The prognosis in patients with gliomas after surgical resection followed by radiotherapy and/or chemotherapy is still very poor. The pro-apoptotic protein Bax, a short-lived protein in cancers, plays important roles in the sensitivity of glioma cells to spontaneous and therapy-induced apoptosis but and its prognostic value in gliomas is unknown. Methods By an immunohistochemical method, we determined Bax protein expression from 96 patients with gliomas after curative resection. Two statistical analyses were performed to evaluate the prognostic significance of Bax protein: an independent continuous and a multivariate categorical analysis, with test/validation set-defined cut points, and Kaplan–Meier estimated outcome measures of overall survival (OS) and relapse-free survival (RFS). Results Bax protein levels in glioblastoma were significantly decreased compared with grade II gliomas. Lower levels of Bax expression confer worse OS (continuous P = 0.025; categorical P = 0.003) and RFS (continuous P = 0.014; categorical P < 0.0001) and negatively correlate with the grades of gliomas. Patients underwent radiotherapy followed by surgical resection showed significantly increased OS (median = 45 vs. 17 months) and RFS (median = 39 vs. 16 months). Patients with higher levels of Bax and radiotherapy showed greatly increased survival rates (median OS = 66 months and median RFS = 105 months). Lower expression of Bax also confers inferior clinical outcome for gliomas patients after chemotherapy with temozolomide (OS and RFS P < 0.0001). Conclusion Decreased expression of Bax correlates with poor clinical outcome in patients with gliomas. We propose that Bax protein levels can be used as a reliable prognostic marker for risk-stratify patients with gliomas after curative resection and radiotherapy and/or chemotherapy.
- Open Access
- 12 May 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (10) , 2462-2469
CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia
Purpose: IL6 promotes tumor growth and signal transduction via both its membrane-bound (CD126) and soluble receptors (sCD126). We aimed to study whether the levels of CD126 expression in chronic lymphocytic leukemic (CLL) cells can predict in vitro and in vivo treatment response. Experimental Design: The levels of membrane-bound CD126 expression were determined on freshly isolated CLL B cells (n = 58) using flow cytometry. These CLL cells were treated with chlorambucil or fludarabine with or without anti-CD126 antibody tocilizumab for 24 hours and IL6-mediated STAT3 transcriptional activity and cell-cycle alteration were evaluated. Results: CD126 surface expression was found in all cases and positively correlated with the levels of in vivo constitutive STAT3 activity. The levels of CD126 expression were significantly and positively correlated with the resistance of CLL cells to in vitro treatment with chlorambucil or fludarabine and poor in vivo treatment response of CLL patients. Blocking IL6 signaling with the anti-CD126 antibody, tocilizumab, had profound effects on STAT3-mediated survival and growth signals: decreased Mcl-1 and Bcl-xL, favoring an apoptotic profile; and decreased p27 with increased cyclin E and CDK2 expression, leading to cell-cycle shift from G0–G1. These tocilizumab-mediated changes induced chemosensitization in resistant CLL cells, with the greatest effect seen in cells with higher CD126 expression (P < 0.001). Conclusions: CLL cells with higher CD126 expression are more resistant to treatment in vivo and in vitro via IL6–CD126–STAT3 axis. Blocking CD126 using tocilizumab sensitizes CLL cells to chemotherapy. Clin Cancer Res; 22(10); 2462–9. ©2015 AACR.
- 12 May 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (10) , 2462-2469
Open AccessCD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia
Purpose: IL6 promotes tumor growth and signal transduction via both its membrane-bound (CD126) and soluble receptors (sCD126). We aimed to study whether the levels of CD126 expression in chronic lymphocytic leukemic (CLL) cells can predict in vitro and in vivo treatment response. Experimental Design: The levels of membrane-bound CD126 expression were determined on freshly isolated CLL B cells (n = 58) using flow cytometry. These CLL cells were treated with chlorambucil or fludarabine with or without anti-CD126 antibody tocilizumab for 24 hours and IL6-mediated STAT3 transcriptional activity and cell-cycle alteration were evaluated. Results: CD126 surface expression was found in all cases and positively correlated with the levels of in vivo constitutive STAT3 activity. The levels of CD126 expression were significantly and positively correlated with the resistance of CLL cells to in vitro treatment with chlorambucil or fludarabine and poor in vivo treatment response of CLL patients. Blocking IL6 signaling with the anti-CD126 antibody, tocilizumab, had profound effects on STAT3-mediated survival and growth signals: decreased Mcl-1 and Bcl-xL, favoring an apoptotic profile; and decreased p27 with increased cyclin E and CDK2 expression, leading to cell-cycle shift from G0–G1. These tocilizumab-mediated changes induced chemosensitization in resistant CLL cells, with the greatest effect seen in cells with higher CD126 expression (P < 0.001). Conclusions: CLL cells with higher CD126 expression are more resistant to treatment in vivo and in vitro via IL6–CD126–STAT3 axis. Blocking CD126 using tocilizumab sensitizes CLL cells to chemotherapy. Clin Cancer Res; 22(10); 2462–9. ©2015 AACR.
- Open Access
- 9 April 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (22) , 32031-32045
STAT3 and NF-κB cooperatively controlin vitrospontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is an adult disease characterized by in vivo accumulation of mature CD5/CD19/CD23 triple positive B cells and is currently incurable. CLL cells undergo spontaneous apoptosis in response to in vitro cell culture condition but the underlying mechanism is unclear. We hypothesize that the sensitivity of CLL cells to spontaneous apoptosis may be associated with the constitutive activities of transcription factors STAT3 and/or NF-κB. We now show that the sensitivity of fresh CLL cells to spontaneous apoptosis is highly variable among different patients during 48 hours’ cell culture and inversely correlated with in vivo constitutively activated STAT3 and NF-κB (p < 0.001). Both activated STAT3 and NF-κB maintain the levels of anti-apoptotic protein Mcl-1/Bcl-xL and autocrine IL-6 production. CLL cells with higher susceptibility to in vitro spontaneous apoptosis show the greatest chemosensitivity (p < 0.001), which is reflected clinically as achieving a complete response (CR) (p < 0.001), longer lymphocyte doubling times (p < 0.01), time to first treatment (p < 0.01), and progression free survival (p < 0.05). Our data suggest that the sensitivity of CLL cells to in vitro spontaneous apoptosis is co-regulated by constitutively activated STAT3 and NF-κB and reflects the in vivo chemo-responsiveness and clinical outcomes.
- 9 April 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (22) , 32031-32045
Open AccessSTAT3 and NF-κB cooperatively controlin vitrospontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is an adult disease characterized by in vivo accumulation of mature CD5/CD19/CD23 triple positive B cells and is currently incurable. CLL cells undergo spontaneous apoptosis in response to in vitro cell culture condition but the underlying mechanism is unclear. We hypothesize that the sensitivity of CLL cells to spontaneous apoptosis may be associated with the constitutive activities of transcription factors STAT3 and/or NF-κB. We now show that the sensitivity of fresh CLL cells to spontaneous apoptosis is highly variable among different patients during 48 hours’ cell culture and inversely correlated with in vivo constitutively activated STAT3 and NF-κB (p < 0.001). Both activated STAT3 and NF-κB maintain the levels of anti-apoptotic protein Mcl-1/Bcl-xL and autocrine IL-6 production. CLL cells with higher susceptibility to in vitro spontaneous apoptosis show the greatest chemosensitivity (p < 0.001), which is reflected clinically as achieving a complete response (CR) (p < 0.001), longer lymphocyte doubling times (p < 0.01), time to first treatment (p < 0.01), and progression free survival (p < 0.05). Our data suggest that the sensitivity of CLL cells to in vitro spontaneous apoptosis is co-regulated by constitutively activated STAT3 and NF-κB and reflects the in vivo chemo-responsiveness and clinical outcomes.
- Open Access
- 4 June 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (26) , 22598-22612
Dynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis
Dynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis
- 4 June 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (26) , 22598-22612
Open AccessDynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis
Dynamin-related protein Drp1 is required for Bax translocation to mitochondria in response to irradiation-induced apoptosis
- Open Access
- 13 March 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (11) , 1709-1719
Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
Key Points: HMGB1 and DNA released from CLL cells induce nurse-like cell differentiation. This differentiation appears TLR9/RAGE dependent.
- 13 March 2014
- Published by American Society of Hematology in Blood
- Vol. 123 (11) , 1709-1719
Open AccessExtracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia
Key Points: HMGB1 and DNA released from CLL cells induce nurse-like cell differentiation. This differentiation appears TLR9/RAGE dependent.